Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Chia-Ching Wang

Description

Summary

This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (HIV)-positive stage II-IV diffuse large B-cell lymphomas. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride may work better in treating patients with HIV-positive diffuse large B-cell lymphomas.

Official Title

Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

Details

Keywords

AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Lymphoma, B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Prednisone, Cortisone, Cyclophosphamide, Rituximab, Doxorubicin, Liposomal doxorubicin, Etoposide, Vincristine, Etoposide phosphate, Podophyllotoxin, Immunological Antineoplastic Agents, Antibodies, Immunoglobulins, Monoclonal Antibodies, Lenograstim, Ibrutinib, Doxorubicin Hydrochloride, Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, Vincristine Sulfate

Eligibility

Locations

  • UCSF Medical Center-Parnassus accepting new patients
    San Francisco California 94143 United States
  • UCLA / Jonsson Comprehensive Cancer Center withdrawn
    Los Angeles California 90095 United States
  • UC San Diego Moores Cancer Center accepting new patients
    La Jolla California 92093 United States

Lead Scientist at UCSF

  • Chia-Ching Wang
    Jackie Wang, MD, is an Assistant Professor at University of California, San Francisco and a faculty member in the Division of Hematology-Oncology at Zuckerberg San Francisco General Hospital. Her research interest is in HIV oncology. She is a member of the AIDS Malignancy Consortium. She is certified to perform high-resolution anoscopy to detect anal dysplasia.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT03220022
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 54 study participants
Last Updated